{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:36:10Z","timestamp":1782383770670,"version":"3.54.5"},"reference-count":31,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Hepatitis C is an important risk factor for cirrhosis and liver cancer in the Taiwanese population. Domestic prisons reported a higher rate of hepatitis C infection than the national average. Efficient and effective treatment of patients with hepatitis C in prisons is required to decrease the number of infections. This study analysed the effectiveness of hepatitis C treatment and its side effects in prison patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This retrospective analysis included adult patients with hepatitis C who received direct-acting antiviral agents between 2018 and 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The special hepatitis C clinics in the two prisons were run by a medium-sized hepatitis C treatment hospital in Southern Taiwan. Three direct-acting antiviral agents, sofosbuvir\/ledipasvir for 12 weeks, glecaprevir\/pibrentasvir for 8 or 12 weeks and sofosbuvir\/velpatasvir for 12 weeks, were adopted based on patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>470 patients were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measure<\/jats:title>\n                    <jats:p>The sustained virological response at 12 weeks after the end of treatment was compared between the different groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most of the patients were men (70.0%) with a median age of 44 years. The most prevalent hepatitis C virus genotype was genotype 1 (44.26%). A total of 240 patients (51.06%) had a history of injectable drug use; 44 (9.36%) and 71 (15.11%) patients were coinfected with hepatitis B virus and HIV, respectively. Only 51 patients (10.85%) had liver cirrhosis. Most patients (98.30%) had normal renal function or no history of kidney disease. The patients had a sustained virological response achievement rate of 99.2%. The average incidence of adverse reactions during treatment was approximately 10%. Many of the adverse reactions were mild and resolved spontaneously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Direct-acting antiviral agents are effective for treating hepatitis C in Taiwanese prisoners. These therapeutics were well-tolerated by the patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070490","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:43:44Z","timestamp":1686141824000},"page":"e070490","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-7800","authenticated-orcid":false,"given":"Yu-Chi","family":"Tsai","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"},{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospitall; College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chou-Yuan","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Hsin","sequence":"additional","affiliation":[{"name":"Aviation Physiology Research Laboratory, Kaohsiung Armed Forces General Hospital Gangshan Branch, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Zhang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"},{"name":"Department of Nursing, Tajen University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2025121409292974000_13.6.e070490.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(09)60231-X"},{"key":"2025121409292974000_13.6.e070490.2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/09540120801926985","article-title":"Risky behaviors for HIV infection among male incarcerated injection drug users in Taiwan: a case-control study","volume":"20","author":"Chen","year":"2008","journal-title":"AIDS Care"},{"key":"2025121409292974000_13.6.e070490.3","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20081045"},{"key":"2025121409292974000_13.6.e070490.4","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007662315835"},{"key":"2025121409292974000_13.6.e070490.5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa301","article-title":"Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan","volume":"7","author":"Yang","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025121409292974000_13.6.e070490.6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jmii.2018.10.002","article-title":"Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings","volume":"52","author":"Chen","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2025121409292974000_13.6.e070490.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191799","article-title":"Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection","volume":"13","author":"Cheng","year":"2018","journal-title":"PLoS ONE"},{"key":"2025121409292974000_13.6.e070490.8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31060"},{"key":"2025121409292974000_13.6.e070490.9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3748\/wjg.v28.i2.263","article-title":"Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison","volume":"28","author":"Chen","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2025121409292974000_13.6.e070490.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clinical Trials"},{"key":"2025121409292974000_13.6.e070490.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"2025121409292974000_13.6.e070490.12","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346"},{"key":"2025121409292974000_13.6.e070490.13","doi-asserted-by":"crossref","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"2025121409292974000_13.6.e070490.14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22045"},{"key":"2025121409292974000_13.6.e070490.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"2025121409292974000_13.6.e070490.16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12861"},{"key":"2025121409292974000_13.6.e070490.17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cmi.2016.09.017","article-title":"Role of assessing liver fibrosis in management of chronic hepatitis C virus infection","volume":"22","author":"Carmona","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2025121409292974000_13.6.e070490.18","doi-asserted-by":"crossref","unstructured":"Chen C-H , Chen C-H , Lin C-L , et al . Real-World safety and efficacy of paritaprevir\/ritonavir\/ombitasvir plus dasabuvir \u00b1 ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep 2019;9. doi:10.1038\/s41598-019-43554-3","DOI":"10.1038\/s41598-019-43554-3"},{"key":"2025121409292974000_13.6.e070490.19","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121409292974000_13.6.e070490.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2005.10.008"},{"key":"2025121409292974000_13.6.e070490.21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2001"},{"key":"2025121409292974000_13.6.e070490.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094791","article-title":"Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection","volume":"9","author":"Hsieh","year":"2014","journal-title":"PLoS One"},{"key":"2025121409292974000_13.6.e070490.23","doi-asserted-by":"publisher","DOI":"10.1086\/587992"},{"key":"2025121409292974000_13.6.e070490.24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J Hepatol"},{"key":"2025121409292974000_13.6.e070490.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.027"},{"key":"2025121409292974000_13.6.e070490.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.025"},{"key":"2025121409292974000_13.6.e070490.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.012"},{"key":"2025121409292974000_13.6.e070490.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22694"},{"key":"2025121409292974000_13.6.e070490.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2011.10.027"},{"key":"2025121409292974000_13.6.e070490.30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2022.01.030","article-title":"Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan","volume":"77","author":"Lai","year":"2022","journal-title":"J Hepatol"},{"key":"2025121409292974000_13.6.e070490.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29109"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:29:38Z","timestamp":1765733378000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2022-070490"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070490","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}